Humanized anti-complement factor Bb antibodies
US-11242382-B2 · Feb 8, 2022 · US
Humanized anti-complement factor Bb antibodies and uses thereof
US11999780B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11999780-B2 |
| Application number | US-202117557318-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2021 |
| Priority date | Apr 20, 2020 |
| Publication date | Jun 4, 2024 |
| Grant date | Jun 4, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
First claim
Opening claim text (preview).
What is claimed is: 1. A nucleic acid or nucleic acid set encoding a humanized antibody that binds specifically to human complement factor Bb protein, wherein the humanized antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27. 2. A vector or vector set comprising the nucleic acid or nucleic acid set of claim 1 . 3. An isolated cell comprising the nucleic acid or nucleic acid set of claim 1 . 4. The isolated cell of claim 3 , wherein the cell is a mammalian cell. 5. The isolated cell of claim 4 , wherein the mammalian cell is selected from human embryonic kidney (HEK) cells, Chinese hamster ovary (CHO) cells, NS0 myeloma cells, SP2 cells, COS cells, and mammary epithelial cells. 6. The nucleic acid or nucleic acid set of claim 1 , wherein the humanized antibody comprises a heavy chain constant region comprising the amino acid sequence of any one of SEQ ID NOsi[H] 28-30. 7. The nucleic acid or nucleic acid set of claim 1 , wherein the humanized antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 31. 8. The nucleic acid or nucleic acid set of claim 6 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain comprising the amino acid sequence of SEQ ID NO: 35. 9. The nucleic acid or nucleic acid set of claim 6 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 35. 10. The nucleic acid or nucleic acid set of claim 6 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 35. 11. The nucleic acid or nucleic acid set of claim 1 , wherein the humanized antibody is selected from the group consisting of an Ig monomer, a Fab fragment, a F(ab′)2 fragment, a scFv, a scAb, and a Fv. 12. The nucleic acid or nucleic acid set of claim 1 , wherein the humanized antibody comprises a heavy chain constant region of the isotype IgG1, IgG2, IgG3, or IgG4. 13. A method of producing a humanized antibody that binds specifically to human complement factor Bb protein, the method comprising culturing the isolated cell of claim 3 to produce the humanized antibody. 14. The method of claim 13 , further comprising isolating the humanized antibody. 15. A composition comprising: a nucleic acid or nucleic acid set encoding a humanized antibody that binds specifically to human complement factor Bb protein, wherein the humanized antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27, and a buffer. 16. A composition comprising: a vector or vector set comprising a nucleic acid or nucleic acid set encoding a humanized antibody that binds specifically to human complement factor Bb protein, wherein the humanized antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27, and a buffer. 17. A composition comprising: an isolated cell comprising a nucleic acid or nucleic acid set encoding a humanized antibody that binds specifically to human complement factor Bb protein, wherein the humanized antibody comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27, and a buffer.
Assignees
Inventors
Classifications
- C07K16/18Primary
against material from animals or humans · CPC title
the antibody targeting a material from animals or humans · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
multispecific · CPC title
Constant or Fc region; Isotype · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11999780B2 cover?
- Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
- Who is the assignee on this patent?
- Genzyme Corp
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).